Nebenwirkungen · Velcade
VELCADE 3.5 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 45
HOS-112808 · Präparat HOS-093755
Tabulated summary of adverse reactions Multiple Myeloma Undesirable effects in Table 7 were considered by the investigators to have at least a possible or probable causal relationship to VELCADE. These adverse reactions are based on an integrated data set of 5,476 patients of whom 3,996 were treated with VELCADE at 1.3 mg/m2 and included in Table 7. Overall, VELCADE was administered for the treatment of multiple myeloma in 3,974 patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 3022ae5ff1e6798c8330868e9a8d642dcb52ef2eb623103839ab5bdac01241de · Zeichen 615–1057 im Abschnitt